US physicians require less clinical trial data than their European counterparts before they are comfortable prescribing biosimilars, according to a new report.

The Decision Resources report found that 33% of surveyed U.S. physicians would prescribe a biosimilar based on information from just one Phase III study, as opposed to 20% of physicians in France and Germany.

US physicians are more comfortable with short duration of clinical trials on the whole, the report added.

Decision Resources product director Michael Malecki said that the desire for trials addressing immunogenicity of biosimilars is greater among European physicians.

“This very likely reflects immunogenicity problems with biosimilars erythropoiesis stimulating agents currently on the market in the EU,” said Malecki.

The report found that US and European physicians place the most trust in biotech companies experienced in manufacturing biologics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.